CRED ERP 25

exclusivity/2 years marketing exclusivity) with an additional one year market exclusivity possible for significant new indications approved within the first 8 years). This is applicable for marketing authorisations (MAs) granted based on so called full dossiers (i.e. article 8(3) 10a and 10b of Directive 2001/83/EC.